Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry

Biomedical Chromatography

Volumn 27, Issue 4, 2013, Pages 466-476

  Lankheet, N A G ^a   Hillebrand, M J X ^a   Rosing, H ^a   Schellens, J H M ^b,c   Beijnen, J H ^a,c   Huitema, A D R ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

LC MS MS; Therapeutic drug monitoring; Tyrosine kinase inhibitors

Indexed keywords

AMINO ACIDS; COLUMN CHROMATOGRAPHY; DRUG PRODUCTS; ENZYME INHIBITION; MASS SPECTROMETRY; PARTICLE SIZE; PATIENT MONITORING; PLASMA (HUMAN);

DASATINIB; ERLOTINIB; GEFITINIB; IMATINIB; LAPATINIB; LC-MS-MS; LC.MS/MS; NILOTINIB; THERAPEUTIC DRUG MONITORING; TYROSINE KINASE INHIBITOR;

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

DASATINIB; ERLOTINIB; GEFITINIB; IMATINIB; LAPATINIB; NILOTINIB; PLASMA PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB;

ACCURACY; ARTICLE; CALIBRATION; CONCENTRATION RESPONSE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; DRUG STABILITY; DRUG STRUCTURE; ELECTROSPRAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIMIT OF QUANTITATION; MONITORING; PARTICLE SIZE; PLASMA; QUALITY CONTROL; REPRODUCIBILITY; REVERSED PHASE LIQUID CHROMATOGRAPHY; SIGNAL NOISE RATIO; STANDARD; SUPERNATANT; TANDEM MASS SPECTROMETRY; VALIDATION STUDY;

EID: 84874944093     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.2814     Document Type: Article

References (36)

1. Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. The Lancet Oncology 2007; 8: 1018-1029.
2. Bai F, Freeman BB, III, Fraga CH, Fouladi M and Stewart CF. Determination of lapatinib (GW572016) in human plasma by liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS). Journal of Chromatography B Analytical Technology in Biomedicine and Life Sciences 2006; 831: 169-175.
3. Bakhtiar R, Lohne J, Ramos L, Khemani L, Hayes M and Tse F. High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry. Journal of Chromatography B Analytical Technology in Biomedicine and Life Sciences 2002; 768: 325-340.
4. Bouchet S, Chauzit E, Ducint D, Castaing N, Canal-Raffin M, Moore N, Titier K and Molimard M. Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS. Clinica Chimica Acta 2011; 412: 1060-1067.
5. Burris HA, III, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O'Neil B, Marcom PK, Ellis MJ, Overmoyer B, Jones SF, Harris JL, Smith DA, Koch KM, Stead A, Mangum S and Spector NL. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. Journal of Clinical Oncology 2005; 23: 5305-5313.
6. Chahbouni A, den Burger JC, Vos RM, Sinjewel A and Wilhelm AJ. Simultaneous quantification of erlotinib, gefitinib, and imatinib in human plasma by liquid chromatography tandem mass spectrometry. Therapeutic Drug Monitoring 2009; 31: 683-687.
7. Couchman L, Birch M, Ireland R, Corrigan A, Wickramasinghe S, Josephs D, Spicer J and Flanagan RJ. An automated method for the measurement of a range of tyrosine kinase inhibitors in human plasma or serum using turbulent flow liquid chromatography-tandem mass spectrometry. Analytical and Bioanalytical Chemistry 2012; 403: 1685-1695. DOI: 10.1007/s00216-012-5970-2 [doi].
8. Dai G, Pfister M, Blackwood-Chirchir A and Roy A. Importance of characterizing determinants of variability in exposure: application to dasatinib in subjects with chronic myeloid leukemia. Journal of Clinical Pharmacology 2008; 48: 1254-1269.
9. de Bruijn P, Sleijfer S, Lam MH, Mathijssen RH, Wiemer EA and Loos WJ. Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis 2010; 51: 934-941.
10. De Francia S, D'Avolio A, De Martino F, Pirro E, Baietto L, Siccardi M, Simiele M, Racca S, Saglio G, Di Carlo F and Di Perri G. New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma. Journal of Chromatography B Analytical Technology in Biomedicine and Life Sciences 2009; 877: 1721-1726.
11. Delbaldo C, Chatelut E, Re M, Deroussent A, Seronie-Vivien S, Jambu A, Berthaud P, Le Cesne A, Blay JY and Vassal G. Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors. Clinical Cancer Research 2006; 12: 6073-6078.
12. Druker BJ. Circumventing resistance to kinase-inhibitor therapy. The New England Journal of Medicine 2006; 354: 2594-2596.
13. Gotze L, Hegele A, Metzelder SK, Renz H and Nockher WA. Development and clinical application of a LC-MS/MS method for simultaneous determination of various tyrosine kinase inhibitors in human plasma. Clinica Chimica Acta 2012; 413: 143-149.
14. Gross ME, Leichman L, Lowe ES, Swaisland A and Agus DB. Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study. Cancer Chemotherapy and Pharmacology 2012; 69: 273-280.
15. Haouala A, Zanolari B, Rochat B, Montemurro M, Zaman K, Duchosal MA, Ris HB, Leyvraz S, Widmer N and Decosterd LA. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. Journal of Chromatography B Analytical Technology in Biomedicine and Life Sciences 2009; 877: 1982-1996.
16. Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, Eckhardt SG, Tolcher A, Britten CD, Denis L, Ferrante K, Von Hoff DD, Silberman S and Rowinsky EK. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. Journal of Clinical Oncology 2001; 19: 3267-3279.
17. Honeywell R, Yarzadah K, Giovannetti E, Losekoot N, Smit EF, Walraven M, Lind JS, Tibaldi C, Verheul HM and Peters GJ. Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry. Journal of Chromatography B Analytical Technology in Biomedicine and Life Sciences 2010; 878: 1059-1068.
18. Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD and Motzer RJ. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemotherapy and Pharmacology 2010; 66: 357-371.
19. Hsieh Y, Galviz G, Zhou Q and Duncan C. Hydrophilic interaction liquid chromatography/tandem mass spectrometry for the simultaneous determination of dasatinib, imatinib and nilotinib in mouse plasma. Rapid Communications in Mass Spectrometry 2009; 23: 1364-1370.
20. Krause DS and Van Etten RA. Tyrosine kinases as targets for cancer therapy. The New England Journal of Medicine 2005; 353: 172-187.
21. Lankheet NA, Blank CU, Mallo H, Adriaansz S, Rosing H, Schellens JH, Huitema AD and Beijnen JH. Determination of sunitinib and its active metabolite N-desethylsunitinib in sweat of a patient. Journal of Analytical Toxicology 2011; 35: 558-565.
22. Larson RA, Druker BJ, Guilhot F, O'Brien SG, Riviere GJ, Krahnke T, Gathmann I and Wang Y. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008; 111: 4022-4028.
23. Larson RA, Yin OQ, Hochhaus A, Saglio G, Clark RE, Nakamae H, Gallagher NJ, Demirhan E, Hughes TP, Kantarjian HM and le Coutre PD. Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase. European Journal of Clinical Pharmacology 2012; 68: 723-733.
24. Masters AR, Sweeney CJ and Jones DR. The quantification of erlotinib (OSI-774) and OSI-420 in human plasma by liquid chromatography-tandem mass spectrometry. Journal of Chromatography B Analytical Technology in Biomedicine and Life Sciences 2007; 848: 379-383.
25. Parise RA, Egorin MJ, Christner SM, Shah DD, Zhou W and Beumer JH. A high-performance liquid chromatography-mass spectrometry assay for quantitation of the tyrosine kinase inhibitor nilotinib in human plasma and serum. Journal of Chromatography B Analytical Technology in Biomedicine and Life Sciences 2009; 877: 1894-1900.
26. Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard MA, Lassalle R, Marit G, Reiffers J, Begaud B, Moore N, Molimard M and Mahon FX. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007; 109: 3496-3499.
27. Ross DM and Hughes TP. Current and emerging tests for the laboratory monitoring of chronic myeloid leukaemia and related disorders. Pathology 2008; 40: 231-246.
28. Sparidans RW, Iusuf D, Schinkel AH, Schellens JHM and Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the light sensitive tyrosine kinase inhibitor axitinib in human plasma. Journal of Chromatography B Analytical Technology in Biomedicine and Life Sciences 2009; 877: 4090-4096.
29. Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, Hendlisz A, Hirte HW, Eder JP, Lenz HJ and Schwartz B. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. The Oncologist 2007; 12: 426-437.
30. Teng JF, Mabasa VH and Ensom MH. The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors. Therapeutic Drug Monitoring 2012; 34: 85-97.
31. US Food and Drug Administration. FDA Guidance for Industry: Bioanalytical Method Validation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research: Rockville, MD, 2001.
32. Viswanathan CT, Bansal S, Booth B, DeStefano AJ, Rose MJ, Sailstad J, Shah VP, Skelly JP, Swann PG and Weiner R. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharmaceutical Research 2007; 24: 1962-1973.
33. Widmer N, Decosterd LA, Leyvraz S, Duchosal MA, Rosselet A, Debiec-Rychter M, Csajka C, Biollaz J and Buclin T. Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability. British Journal of Cancer 2008; 98: 1633-1640.
34. Yau T, Chen PJ, Chan P, Curtis CM, Murphy PS, Suttle AB, Gauvin J, Hodge JP, Dar MM and Poon RT. Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics. Clinical Cancer Research 2011; 17: 6914-6923.
35. Zhao M, Hartke C, Jimeno A, Li J, He P, Zabelina Y, Hidalgo M and Baker SD. Specific method for determination of gefitinib in human plasma, mouse plasma and tissues using high performance liquid chromatography coupled to tandem mass spectrometry. Journal of Chromatography B Analytical Technology in Biomedicine and Life Sciences 2005; 819: 73-80.
36. Zhao M, Rudek MA, He P, Hafner FT, Radtke M, Wright JJ, Smith BD, Messersmith WA, Hidalgo M and Baker SD. A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay. Journal of Chromatography B Analytical Technology in Biomedicine and Life Sciences 2007; 846: 1-7.